Current report filing

Note 24 - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details)

v3.8.0.1
Note 24 - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Tc99m tilmanocept sales revenue $ 9,000 $ 18,000 $ 4,000 $ 9,000 $ 6,000 $ 9,000 $ 4,000 $ 39,601 $ 19,075 $ 13,200
Tc99m tilmanocept license revenue 1,296,000 246,000 254,000 250,000 550,000 250,000 83,000 1,795,625 1,133,333 300,000
Grant and other revenue 1,022,000 511,000 917,000 686,000 540,000 477,000 654,000 190,000 3,136,408 1,860,953 1,740,896
Gross profit 975,000 1,821,000 1,166,000 947,000 796,000 1,034,000 904,000 276,000 4,909,374 3,010,135 2,051,470
Operating expenses 4,215,000 2,731,000 3,407,000 4,705,000 4,256,000 5,947,000 4,348,000 6,900,000 15,058,116 21,450,875 24,642,962
Loss from operations (3,240,000) (910,000) (2,241,000) (3,758,000) (3,463,000) (4,912,000) (3,443,000) (6,623,000) (10,148,742) [1] (18,440,740) [1] (22,591,492)
Loss from continuing operations (2,118,000) (1,761,000) (817,000) (2,682,000) (1,946,000) (6,509,000) (8,171,000) (5,983,000)      
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax (1,764,000) 1,702,000 (5,865,000) (1,004,000) (564,000) (1,562,000) (1,520,000) (1,309,000) (6,931,137) (4,518,938) [2] (5,367,801)
Net loss attributable to common stockholders $ (3,882,000) $ (59,000) $ (6,681,000) $ (3,686,000) $ (2,510,000) $ (8,071,000) $ (9,691,000) $ (7,337,000) $ (14,308,383) $ (27,608,680) $ (35,726,669)
Loss per common share (basic and diluted):                      
Continuing operations (in dollars per share) $ (0.01) [3] $ (0.01) [3] $ 0 [3] $ (0.02) [3] $ (0.02) [3] $ (0.04) [3] $ (0.05) [3] $ (0.04) [3] $ (0.05) $ (0.15) $ (0.20)
Discontinued operations (in dollars per share) (0.01) [3] 0.01 [3] (0.04) [3] 0 [3] 0 [3] (0.01) [3] (0.01) [3] (0.01) [3] (0.04) (0.03) (0.04)
Attributable to common stockholders (in dollars per share) $ (0.02) [3] $ 0 [3] $ (0.04) [3] $ (0.02) [3] $ (0.02) [3] $ (0.05) [3] $ (0.06) [3] $ (0.05) [3] $ (0.09) $ (0.18) $ (0.24)
Tc99m tilmanocept sales revenue $ 9,000 $ 18,000 $ 4,000 $ 9,000 $ 6,000 $ 9,000 $ 4,000 $ 39,601 $ 19,075 $ 13,200
Tc99m tilmanocept license revenue 1,296,000 246,000 254,000 250,000 550,000 250,000 83,000 1,795,625 1,133,333 300,000
Grant and other revenue 1,022,000 511,000 917,000 686,000 540,000 477,000 654,000 190,000 3,136,408 1,860,953 1,740,896
Gross profit 975,000 1,821,000 1,166,000 947,000 796,000 1,034,000 904,000 276,000 4,909,374 3,010,135 2,051,470
Operating expenses 4,215,000 2,731,000 3,407,000 4,705,000 4,256,000 5,947,000 4,348,000 6,900,000 15,058,116 21,450,875 24,642,962
Loss from operations (3,240,000) (910,000) (2,241,000) (3,758,000) (3,463,000) (4,912,000) (3,443,000) (6,623,000) (10,148,742) [1] (18,440,740) [1] (22,591,492)
Loss from continuing operations (2,118,000) (1,761,000) (817,000) (2,682,000) (1,946,000) (6,509,000) (8,171,000) (5,983,000)      
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax (1,764,000) 1,702,000 (5,865,000) (1,004,000) (564,000) (1,562,000) (1,520,000) (1,309,000) (6,931,137) (4,518,938) [2] (5,367,801)
Net loss attributable to common stockholders $ (3,882,000) $ (59,000) $ (6,681,000) $ (3,686,000) $ (2,510,000) $ (8,071,000) $ (9,691,000) $ (7,337,000) $ (14,308,383) $ (27,608,680) $ (35,726,669)
[1] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[2] Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).
[3] Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation.